• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Carcinoma in situ of the bladder.

作者信息

Hudson M A, Herr H W

机构信息

Division of Urological Surgery, Washington University School of Medicine, St. Louis, Missouri.

出版信息

J Urol. 1995 Mar;153(3 Pt 1):564-72. doi: 10.1097/00005392-199503000-00002.

DOI:10.1097/00005392-199503000-00002
PMID:7861485
Abstract
摘要

相似文献

1
Carcinoma in situ of the bladder.膀胱原位癌
J Urol. 1995 Mar;153(3 Pt 1):564-72. doi: 10.1097/00005392-199503000-00002.
2
Blood group isoantigen deletion in carcinoma in situ of the urinary bladder.
Cancer. 1979 Feb;43(2):661-8. doi: 10.1002/1097-0142(197902)43:2<661::aid-cncr2820430238>3.0.co;2-7.
3
Multiple cell markers in bladder cancer. Principles and clinical applications.
Urol Clin North Am. 1984 Nov;11(4):609-16.
4
Expression of blood-group-related antigens in carcinoma in situ of the urinary bladder.血型相关抗原在膀胱原位癌中的表达
Cancer. 1985 Aug 15;56(4):797-804. doi: 10.1002/1097-0142(19850815)56:4<797::aid-cncr2820560417>3.0.co;2-h.
5
[ABH isoantigen of superficial urothelial tumor and carcinoma in situ of the bladder by the avidin-biotin peroxidase complex(ABC) method].[应用抗生物素蛋白-生物素过氧化物酶复合物（ABC）法检测膀胱浅表性尿路上皮肿瘤及原位癌中的ABH同种抗原]
Nihon Hinyokika Gakkai Zasshi. 1983 Aug;74(8):1326-38. doi: 10.5980/jpnjurol1928.74.8_1326.
6
Mechanisms of action of intravesical treatment. Effect on the ABH surface antigens of urothelial cells.
Cancer Chemother Pharmacol. 1983;11 Suppl:S74-8.
7
ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride.
Urol Res. 1981;9(3):153-6. doi: 10.1007/BF00254411.
8
Estimation of ABO(H) isoantigen expression in bladder tumors.膀胱肿瘤中ABO(H)同种抗原表达的评估。
J Urol. 1985 Jan;133(1):25-8. doi: 10.1016/s0022-5347(17)48770-2.
9
[Conservation or loss of membrane antigens of the ABH blood group and their precursor substance. Prognostic importance for tumors of the bladder].[ABH血型膜抗原及其前体物质的保留或丧失。对膀胱癌的预后意义]
Acta Urol Belg. 1983;51(1):12-7.
10
Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra.评估和治疗伴有或不伴有前列腺尿道受累的膀胱原位癌的现有方法。
Int J Urol. 1995 Jun;2 Suppl 2:8-22. doi: 10.1111/j.1442-2042.1995.tb00475.x.

引用本文的文献

1
Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.不同阶段尿路上皮膀胱癌的蛋白质基因组学研究揭示了乳头状癌和原位癌的不同分子特征。
Nat Commun. 2023 Sep 13;14(1):5670. doi: 10.1038/s41467-023-41139-3.
2
Current Concepts in the Management of Non-Muscle Invasive Bladder Cancer.非肌肉浸润性膀胱癌管理的当前概念
Indian J Surg Oncol. 2017 Sep;8(3):397-402. doi: 10.1007/s13193-016-0585-2. Epub 2017 Jun 6.
3
Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
非肌肉浸润性膀胱癌的复发机制——临床视角。
Nat Rev Urol. 2022 May;19(5):280-294. doi: 10.1038/s41585-022-00578-1. Epub 2022 Mar 31.
4
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 全文
Can Urol Assoc J. 2021 Aug;15(8):E424-E460. doi: 10.5489/cuaj.7367.
5
Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study.经内镜消融治疗高危表浅上尿路上皮癌患者在不适合根治性肾输尿管切除术的情况下联合使用派姆单抗和卡介苗治疗的 II 期研究方案。
BMJ Open. 2019 Dec 3;9(12):e027066. doi: 10.1136/bmjopen-2018-027066.
6
Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer.派姆单抗联合卡介苗用于高危非肌肉浸润性膀胱癌患者的 I 期研究方案。
BMJ Open. 2019 Jul 17;9(7):e028287. doi: 10.1136/bmjopen-2018-028287.
7
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.经尿道膀胱内灌注卡介苗治疗可降低高危非肌层浸润性膀胱癌患者的复发和进展风险，且疗效持久。
World J Urol. 2019 Jan;37(1):155-163. doi: 10.1007/s00345-018-2375-7. Epub 2018 Jun 15.
8
Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder.核基质蛋白22在膀胱冲洗液细胞学检查中对膀胱癌风险分层的有效性
World J Oncol. 2013 Jun;4(3):151-157. doi: 10.4021/wjon677w. Epub 2013 Jul 15.
9
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma of the Bladder who failed Bacillus Calmette Guerin (NCT01259063).依维莫司与膀胱内吉西他滨用于卡介苗治疗失败的原发性或继发性膀胱癌患者的单臂I/II期研究（NCT01259063）。
Bladder Cancer. 2017 Apr 27;3(2):113-119. doi: 10.3233/BLC-170095.
10
Usefulness of urine cytology as a routine work-up in the detection of recurrence in patients with prior non-muscle-invasive bladder cancer: practicality and cost-effectiveness.尿细胞学检查作为既往非肌层浸润性膀胱癌患者复发检测常规检查的实用性和成本效益
Korean J Urol. 2014 Oct;55(10):650-5. doi: 10.4111/kju.2014.55.10.650. Epub 2014 Oct 10.